Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
AMES, Iowa, Aug. 29, 2017 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the following investor conferences in September:
- Baird Global Healthcare Conference on September 7 at 1:25pm ET in New York City
- Cantor Fitzgerald Global Healthcare Conference on September 25 at 4:10pm ET in New York City
A live webcast of both conference presentations will be on the Company's website at www.newlinkgenetics.com in the "Investors & Media" section under "Events and Presentations."
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. Indoximod is being evaluated in combination with treatment regimens including PD-1 checkpoint blockade, cancer vaccines, and chemotherapy across multiple indications such as melanoma, prostate cancer, acute myeloid leukemia, and pancreatic cancer. For more information, please visit http://www.newlinkgenetics.com.
Investor Contact: Lisa Miller Director of Investor Relations NewLink Genetics (515) 598-2555 [email protected] Media Contact: Andrew Mastrangelo AVP, Public & Media Relations LaVoieHealthScience 617-374-8800, ext. 108 [email protected]
